Ultragenyx Pharmaceutical Inc. has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DTX401 AAV gene therapy (pariglasgene brecaparvovec) as a treatment for Glycogen Storage Disease Type Ia (GSDIa). The submission is supported by clinical data from 52 treated patients with up to six years of follow-up, showing significant reductions in daily cornstarch intake and improvements in glycemic control, fasting tolerance, and patient quality of life. The FDA previously granted rolling review, allowing Ultragenyx to submit modules of the BLA on an ongoing basis, and the company has now completed the process with the submission of the final chemistry, manufacturing, and controls module.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-337099), on December 30, 2025, and is solely responsible for the information contained therein.